Development of a novel glutathione repleting agent, L-2-oxothiazolidine-4-carboxylic acid (Procysteine®)

References

• MEISTER A: Selective modification of glutathione meta- bolls= Science (1983) 220:472–477.
   Google Scholar
• Pioneering review on the importance of glutathione and the potential for modification of glutathione metabolism,
   Google Scholar
• MEISTER A: New developments in glutathione metabo-lism and their potential application in therapy. Hepa-tology (1984) 4:739–742.
   PubMed Web of Science ®Google Scholar
• PACHT ER, TIMERMAN AP, LYKENS MG, MEROLA AJ: Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest (1991) 100:1397–1403.
   PubMed Web of Science ®Google Scholar
• CANTIN AM, BEGIN R: Glutathione and inflammatory disorders of the lung. Lung (1991) 169:123–138.
   PubMed Web of Science ®Google Scholar
• BERNARD GR: N-acetylcysteine in experimental and clinical acute lung injury. Am. J. Med. (1991) 91:3C-54S–59S.
   Google Scholar
• Demonstrated efficacy of antioxidant treatment for ARDS.
   Google Scholar
• REPINE JE: Sdentific perspectives on adult respiratory distress syndrome. Lancet (1992) 339:466-469.Review of importance of oxidative stress in ARDS.
   Google Scholar
• BUHL R, HOLROYD KJ, MASTRANGELI A, CANTIN AM, JAFFE HA, WELLS FB, SALTINI C, CRYSTAL RG: Systemic glutathione deficiency in symptom-free HIV-seroposi-tive individuals. Lancet (1989) 2:1294–1298.
   PubMed Web of Science ®Google Scholar
• Report of glutathione depletion in HIV-infected patients.
   Google Scholar
• ECK HP, GMUNDER H, HARTMANN M, PETZOLDT D, DANIEL V, DROEGE W: Low concentrations of acid-sol-uble thiol (cysteine) in the blood plasma of HIV-1 Infected patients. Biol. Chem. Hoppe-Seyler (1989) 370:101–108.
   PubMed Web of Science ®Google Scholar
• Report of glutathione depletion in HIV-infected patients.
   Google Scholar
• GIORGI G, MICHELL L, FIASCHI AT, DAL PRA P, BOZZO M: Glutathione deficiency in human HIV infection. Pharm. Res. (1990) 22\(suppl. 2):231.
   Google Scholar
• ROEDERER M, STAAL FJT, OSADA H, HERZENBERG LA: CD4 and CD8 T-cells with high intracellular glutathione levels are selectively lost as the IIIV infection pro-gresses. Intern at. Immun. (1991) 3:933–937.
   PubMed Web of Science ®Google Scholar
• STAAL FJT, ROEDERER M, ISRAELSKI DM, BUBP J, MOLE LA, MCSHANE D, DERESINSKI SC, ROSS W, SUSSMAN H, RAJU PA, ANDERSON MT, MOORE W, ELA SW, HERZEN-BERG LA: Intracellular glutathione levels in T-cell sub-sets decrease in HIV-infected individuals. AIDS Res. Human Retrovir. (1992) 8:305–311.
   PubMed Web of Science ®Google Scholar
• BUHL R: imbalance between oxidants and antioxidantsIn the lungs of HIV-seropositive Individuals. Chem-Bio Interactions (1994) 91:147–158.
   PubMed Web of Science ®Google Scholar
• WITSCHI A, REDDY S, STOFER B, LAUTERBURG BH: Thesystemic availability of oral glutathione. Eur. J. Clin. Pharmacol. (1992) 43:667–669.
   PubMed Web of Science ®Google Scholar
• RICHMAN PG, MEISTER A: Regulation of y- glutamyl-cys-teine synthetase by nonallosteric feedback inhibition by glutathione. J. Biol. Chem. (1975) 250:1422–1426.
   PubMed Web of Science ®Google Scholar
• DENEKE SM, FANBURG BL: Regulation of cellular giu-tathione. Amer. Physio. Soc. (1989) 257:163–173.
   PubMed Web of Science ®Google Scholar
• HENNIG B, CHOW CK: Lipid peroxidation and endothe-lial cell injury: implications in atherosclerosis. Free Rad. Biol. Med. (1988) 4:99–106.
   PubMed Web of Science ®Google Scholar
• MLTRAKAMI K, KONDO T, OHTSUKA Y, FUJIWARA Y, SHIMADA M, KAWAKAMI Y: Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism (1989) 38:753–758.
   PubMed Web of Science ®Google Scholar
• FLAHERTY JT, WEISFELDT ML: Reperfusion injury. Free Rad. Biol. Med. (1988) 5:409419.
   Google Scholar
• SHUG AL, MADSEN DC: Protection of the ischemic rat heart by Procysteine and amino acids. J. Nutr. Biochem. (1994) 5:356–359.
   Web of Science ®Google Scholar
• BAKER GL, CORRY RJ, AUTOR AP: Oxygen free radical induced damage in kidneys subjected to warm ischemia and reperfusion. Ann. Surg. (1985) 202:628–641.
   PubMed Web of Science ®Google Scholar
• OLANOW CW: An introduction to the free radical hy-pothesis in Parkinson's disease. Ann. Neurol. (1992) 32:S2–S9.
   PubMedGoogle Scholar
• JENNER P: Oxidative damage in neurodegenerative dis-ease. Lancet (1994) 344:796–798.
   PubMed Web of Science ®Google Scholar
• MORRONE A, BARTOLI F, TRAVAGLINO C, PASSI S, IP-POLITO F: Antioxidant status and STD in migrants from sub-Saharian African countries. International Conference on AIDS (1993) 1:674.
   Google Scholar
• PICARDO M, PASSI S, MORRONE A, BARTOLI F, DI CARLO A, IPPOLITO F: Blood deficiency of antioxidant status and polyunsaturated fatty adds as possible risk factors in the onset and development of AIDS. International Conference on AIDS (1993) 1:293.
   Google Scholar
• DELATOUR F, PREVOT MH, MARQUETTY C, GOURGEROT-POCIDALO M: Total glutathione concentration in plasma of infected patients and HIV disease progres-sion. Conference on Oxidative Stress, Cell Activation and Viral Infection (1993) 1:68.
   Google Scholar
• SMITH CV, HANSEN TN, HANSON IC, SHEARER WT: Glu-tathione concentrations in plasma and blood are mark-edly decreased in HIV-infected children. International Conference on AIDS (1990) 6:368.
   Google Scholar
• LIANG C-M, SHIH JW, ALTER HJ, GEYER SJ, EPSTEIN JS: Analysis of glutathione levels in whole blood of HIV-se-ropositive persons. International Conference on AIDS (1987) 1:2602.
   Google Scholar
• STAAL FJT, ROEDERER M, HERZENBERG LA: Glutathioneand immunophenotypes of T and B lymphocytes in 111V-infected individuals. Ann. N.Y. Acad. Sci. (1992) 651:453463.
   Google Scholar
• ECK HP, STAHL-HENNING C, HUNSMANN G, DROEGE W:Metabolic disorder as early consequence of simian
   Google Scholar
• Immunodeficiency virus infection in rhesus macaques. Lancet (1991) 338:346–347.
   PubMed Web of Science ®Google Scholar
• HEFFNER JE, REPINE JE: State of the art: pulmonarystrategies of antioxidant defense. Am. Rev. Respir. Dis. (1989) 140:531–554.
   PubMed Web of Science ®Google Scholar
• BALDWIN SR, GRUM CM, BOXER LA, SIMON RH, KETAI LH,DEVALLLJ: Oxidant activity in expired breath of patients with adult respiratory distress syndrome. Lancet (1986) 1:11–13.
   PubMed Web of Science ®Google Scholar
• SZNAJDER JI, FRAIMAN A, HALL JB, SANDERS W, SCHMIDTG, CRAWFORD G, NAHUM A, FACTOR P, WOOD LDH: Increased hydrogen peroxide in the expired breath of patients with acute hypoxemic respiratory failure. Chest (1989) 96:606–612.
   PubMed Web of Science ®Google Scholar
• HARLAN JM, KILLEN PD, HARKER LA, STRIKER GE: Neutro-phil-mediated endothelial injury in vitro. J. Clin. Invest. (1981) 68:1394–1403.
   PubMed Web of Science ®Google Scholar
• SHASBY DM, VANBENTHUYSEN KM, TATE RM, SHASBY SS, MCMURTRY I, REPINE JE: Granulocytes mediate acute edematous lung injury in rabbits and in isolated rabbit lungs perfused with phorbol myristate acetate: role of oxygen radicals. Am. Rev. Respir. Dis. (1982) 125:443–447.
   PubMed Web of Science ®Google Scholar
• FLICK MR, PEREL A, STAUB NC; Leukocytes are required for increased lung microvascular permeability after microembolization in sheep. Circ. Res. (1981) 48:344–351.
   PubMed Web of Science ®Google Scholar
• TATE RM, VANBENTHUYSEN KM, SHASBY DM, MCMUR-TRY IF, REPINE JE: Oxygen-radical-mediated permeabil-ity edema and vasoconstriction in isolated perfused rabbit lungs. Am. Rev. Respir. Dis. (1982) 126:802–806.
   PubMed Web of Science ®Google Scholar
• JOHNSON KJ, FANTONE JC,III, KAPLAN J, WARD PA: In vivo damage of rat lungs by oxygen metabolites. J. Clin. Invest. (1981) 67:983–993.
   PubMed Web of Science ®Google Scholar
• MARTIN WJ,I1, GADEK JE, HUNNINGHAICE GW, CRYSTALRG: Oxidant injury of lung parenchymal cells. J. Clin. Invest. (1981) 68:1277–1288.
   PubMed Web of Science ®Google Scholar
• COCHRANE CG, SPRAGG R, REVAK SD: Pathogenesis ofthe adult respiratory distress syndrome - evidence of oxidant activity in bronchoaiveolar lavage fluid. J. Clin. Invest. (1983) 71:754–761.
   PubMed Web of Science ®Google Scholar
• MARTENSSON J, JAIN A, FRAYER W, MEISTER A: Glu-tathione metabolism in the lung: inhibition of its syn-thesis leads to lamellar body and mitochondrial defects. Proc. Natl. Acad. Sci. USA (1989) 86:5296–5300.
   PubMed Web of Science ®Google Scholar
• SUTTORP N, TOEPFER W, ROKA L: Antioxidant defense mechanisms of endothelial cells: glutathione redox cycle versus catalase. Am.J.Physiot (1986) 251:C671–C680.
   Web of Science ®Google Scholar
• MARTENSSON J, JAIN A, MEISTER A: Glutathione is re-quired for intestinal function. Proc. Natl. Acad. Sci. USA (1990) 87:1715–1719.
   PubMed Web of Science ®Google Scholar
• MARTENSSON J, JAIN A, STOLE E, FRAYER W, AULD PAM, MEISTER A: inhibition of glutathione synthesis in the newborn rat: a model for endogenously produced oxi-dative stress. P-ot. Natl. Acad. Sci. USA (1991) 88:9360–9364.
   PubMed Web of Science ®Google Scholar
• WELLNER VP, ANDERSON ME, PURI RN, JENSEN GL, MEIS-TER A: Radioprotection by glutathione eaten transport of glutathione ester into human lymphoid cells and fibroblasts. Proc. Natl. Acad. Sci. USA (1984) 81:4732–4735.
   PubMed Web of Science ®Google Scholar
• ANDERSON ME, POWRIE F, PURI RN, MEISTER A: Glu-tathione monoethyl eaten preparation, uptake by tis-sues, and conversion to glutathione. Arch. Biochem. Biophys. (1985) 239:538–548.
   PubMed Web of Science ®Google Scholar
• Use of glutathione mono-esters to increase tissue glutathione.
   Google Scholar
• LEVY EJ, ANDERSON ME, MEISTER A: Transport of glu-tathione diethyl ester into human cells. Proc. Natl. Acad. Sci. USA (1993) 90:9171–9175.
   PubMed Web of Science ®Google Scholar
• Use of glutathione di-esters to increase tissue glutathione.
   Google Scholar
• HIRANO T, TAKEUCHI S: Glutathione isopropyl ester (YM-737), a glutathione derivative, protects the exo-crine pancreas in rats with caerulein-induced pancrea-titis. Med.Sci. Res. (1993) 21:915–916.
   Google Scholar
• NEUSCHWANDER-TETRI BA, FERRELL LD, SUKHABOTE RJ,GRENDELL JH: Glutathione monoethyl ester ameliorates caerulein-induced pancreatitis in the mouse. J. Clin. Invest. (1992) 89:109–116.
   PubMed Web of Science ®Google Scholar
• MARTENSSON J, MEISTER A: Mitochondrial damage inmuscle occurs after marked depletion of glutathione and is prevented by giving glutathione monester. Proc. Natl. Acad. Sci. USA (1989) 86:471–475.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, CRAWFORD JM, HOLDEN SA, UN Y, CATH-CART KNS, LUCHETTE CA, FLATOW J: Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer (1988) 62:1275–1281.
   PubMed Web of Science ®Google Scholar
• GUARNIERI C, TURINE'l 10 B, COLI G, MUSCARI C, CAT-TABRIGA I, VAONA I, FINELLI C, PIGINI F, CALDARERA CM: Effect of glutathione monethyl ester on glutathione level and cardiac energetics in reperfused pig heart. Res. Commun. Chem. Pathol. Pharmacol. (1993) 81:33–44.
   PubMedGoogle Scholar
• BOTTJE W, GLAHN R, NEJAD H, BEERS K, HOLMES K: Glutathione mono-ethyl ester may suppress renal cor-tical perfusion in the rabbit. Med. Sci. Res. (1989) 17:991–993.
   Google Scholar
• ANDERSON ME, NAGANUMA A, MEISTER A: Protection against cisplatin toxicity by administration of glu-tathione ester. FASEB J. (1990) 4:3251–3255.
   PubMed Web of Science ®Google Scholar
• OLNEY JW, HO OL, RHEE V: Cytotoxic effects of acidic and sulphur containing amino adds on the infant mouse central nervous system. Exp. Brain Res. (1971) 14:61–76.
   PubMed Web of Science ®Google Scholar
• KARLSEN RL, GROFOVA I, MALTHE-SORENSSEN D, FON-NUM F: Morphological changes in rat brain induced by L-cysteine injection in newborn animals. Brain Research (1981) 208:167–180.
   PubMed Web of Science ®Google Scholar
• PRESCOTT LF, CRITCHLEY JAJH: The treatment of acetaminophen poisoning. Ann. Rev. Pharmacol. ToxicoL (1983) 23:87–101.
   PubMed Web of Science ®Google Scholar
• BOWMAN G, BACKER U, LARSSON S, MELANDER B, WHA-LANDER L: Oral acetylcysteine reduces excerbation rate In chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Disease. Eur.J. Resp. Dis. (1983) 64:405–415.
   PubMedGoogle Scholar
• HOLDINESS MR: Clinical pharmacokinetics of N-acetyl-cysteine. din. Pharmacokinet. (1991) 20:123–134.
   PubMed Web of Science ®Google Scholar
• OLSSON B, JOHANSSON M, GABRIELSSON J, BOLME P:Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur.j Clin. Pharmacol. (1988) 34:77–82.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON JM, MEISTER A: Stimulation of hepatic glutathione formation by administration of L-2-oxothia 7olidine-4-carboxylate, a 5-oxo-L-prolinase sub-strate. Proc. Natl, Acad. Sci. USA (1981) 78:936–939.
   PubMed Web of Science ®Google Scholar
• Use of OTC to replete tissue glutathione.
   Google Scholar
• VAN DER WERF P, ORLOWSKI M, MEISTER A: Enzymatic conversion of 5-oxo-L-proline (L-pyrrolidone carboxy-late) to L-glutamate coupled with cleavage of adenosine triphosphate to adenosine diphosphate, a reaction in the yglutamyl cycle. Proc. Natl, Acad. Sci. USA (1971) 68:2982–2985.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON pi, BOETTCHER B, MEISTER A: Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc. Natl. Acad. Sci. USA (1982) 79:6246–6249.
   PubMed Web of Science ®Google Scholar
• GOLDBERG DI, MADSEN D, ROWE WE, WEBB L, YOUNG S, JOHNSON RC: Absorption, distribution, metabolism and excretion of orally administered [14C] Procysteine® in rats. International Conference on AIDS (1992).
   Google Scholar
• FREE RADICAL SCIENCES, INC.: Unpublished.
   Google Scholar
• MEISTER A, ANDERSON ME, HWANG O: Intracellular cysteine and glutathione delivery systems. J. Amer. Coll. Nutr. (1986) 5:137–151.
   PubMed Web of Science ®Google Scholar
• TANAKA FL TAKAHASHI K, OGURA M: Metabolic fate of cysteine sulfur in growing rats at various dietary pro-tein levels. J. Nutr. Sci. Vitaminol. (1993) 39:507–516.
   PubMed Web of Science ®Google Scholar
• TANAKA H, NAICATOMI Y, MORI M, OGURA M: Metabo-lism of methionine and cysteine in growing rats at various dietary protein levels. Agric. Biol. Chem. (1990) 54:2093–2099.
   Web of Science ®Google Scholar
• MARTENSSON J: Unpublished.
   Google Scholar
• KAEFFER N, PETIT J, DIEU B, HECKETSWEILER B, LE-MELAND JF, ROSE F, GOLDBERG D, LEREBOURS E: L-2-oxothiazolidine-4-carboxylic acid as a cysteine precursor in acute experimental sepsis in rats: effects on tissue glutathione and cysteine levels. First European Workshop on Glutathione (1993).
   Google Scholar
• ANDERSON ME, MEISTER A: Marked increase of cysteine levels in many regions of the brain after ailminIqtration of 2-oxothiazolidine-4-carboxylate. FASEB J. (1989) 3:1632–1636.
   PubMed Web of Science ®Google Scholar
• OTC crosses blood brain barrier.
   Google Scholar
• MESINA JE, PAGE RH, HETZEL FW, CHOPP M: Administra- tion of L-2-oxothiazolidine-4-carboxylate increases glu-tathione levels in rat brain. Brain Research (1989) 478:181–183.
   PubMed Web of Science ®Google Scholar
• OTC crosses blood brain barrier.
   Google Scholar
• MOSLEN MT, HARPER BL, ROY D: Effects of a cysteine precursor, L-2-oxothiazolicline-carboxylate, nutritional status, and sex on tissue glutathione and hepatic GSH-utilizing enzymes of CD-1 mice. Res. Commun. Chem. Pathol. Pharmacol. (1988) 61:49–63.
   PubMedGoogle Scholar
• BRODEUR J, GOYAL R: Effect of a cysteine prodrug, L-2-oxothiazolidine-4-carboxylic add, on the metabo-lism and toxidty of bromobenzene: an acute study. Can. Physiol . PharmacoL (1987) 65:816–822.
   PubMed Web of Science ®Google Scholar
• MOSLEN MT, WHITEHEAD RF, FERGUSON AE, KANZ ME: Protection by L-2-oxothiazolidine-4-carboxylate, a cys-teine prodrug, against 1,1-dichloroethylene hepato-toxicty in rats is associated with decreases in toxin metabolism and cytochrome P-450. J. Pharmacol. Exp 7her. (1989) 248:157–163.
   PubMed Web of Science ®Google Scholar
• MILLER LF, RUMACK BH: Clinical safety of high oral doses of acetylcysteine. Seminars in Oncology (1983) 10:76–85.
   PubMed Web of Science ®Google Scholar
• TAYLOR CG, BAUMAN PF, SIKORSKI B, BRAY TM: Eleva-tion of lung glutathione by oral supplementation of L-2-oxothiazolidine-4-carboxylate protects against oxygen toxicity in protein-energy malnourished rats. FASEBJ. (1992) 6:3101–3107.
   PubMed Web of Science ®Google Scholar
• McCORD JM: Superoxide radical: a likely link betweenreperfusion injury and inflammation. Free Rad. Biol. Med. (1986) 2:325–345.
   Web of Science ®Google Scholar
• ZWEIER JL: Measurement of superoxide-derived freeradicals in the reperfused heart. J. Biol. Chem. (1988) 263:1353–1357.
   PubMed Web of Science ®Google Scholar
• CURELLO S, CECONI C, BIGOLI C, FERRARI R, ALBERTINIA, GUARNIERI C: Changes in the cardiac glutathione status after ischemia and reperfusion. Experientia (1985) 41:42–43.
   PubMedGoogle Scholar
• FORMAN MB, PUETT DW, CATES CU, MCCROSKEY DE, BECKMAN JK, GREENE HL, VIRMANI R: Glutathione redox pathway and reperfusion injury - effect of N-acetylcys-teine on infarct size and ventricular function. Circula-tion (1988) 78:202–213.
   PubMed Web of Science ®Google Scholar
• BREBOROWICZ A, WITOWSKI J, MARTIS L, OREOPOULOS DG: Enhancement of viability of human peritoneal mesothelial cells with glutathione precursor: L-2-oxothiarolidine-4-carboxylate. Adv. Peritoneal Dial. (1993) 9:21–24.
   PubMedGoogle Scholar
• LASH LH, HAGEN TM, JONES DP: Exogenous glutathioneprotects intestinal epithelial cells from oxidative injury. Proc. Natl. Acad. Sci. USA (1986) 83:4641–4645.
   PubMed Web of Science ®Google Scholar
• WHITE RD, RICE DW, WILSON DM, GOLDBERG DI, ROWE WB, MADSEN DC: Acute toxicity in neonatal rats and young adult dogs, rats and mice intravenously admin-istered L-2-oxothiazolidine-4-carboxylate. J. Am. Coll. Tox. (1992) 1:164–165–
   Google Scholar
• WHITE RD, WILSON DM, GLOSSON JA, MADSEN DC, ROWE WB, GOLDBERG DI: Toxicity evaluations of L-cystehle and ProcysteineTm, a cysteine prodrug, given once intravenously to neonatal rats. Toxicol. Lett. (1993) 69:15–24.
   PubMed Web of Science ®Google Scholar
• KALAYJIAN RC, SKOWRON G, EMGUSHOV R-T, CHANCE M, SPELL SA, BORUM PR, WEBB LS, MAYER KH, JACKSON JB, YEN-LIEBERMAN B, STORY KO, ROWE WB, THOMPSON K, GOLDBERG D, TRIMBO S, LEDERMAN MM: A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic add (Procysteine) in asymptomatic HIV-in-fected subjects. J. AIDS (1994) 7:369–374.
   PubMedGoogle Scholar
• PORTA P, AEBI S, SUMMER K, LAUTERBURG BH: L-2-ox-thiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. J. Pharmacol. Exp. Ther. (1991) 257:331–334.
   PubMed Web of Science ®Google Scholar
• GIORGI G, MICHELI L, FIASCHI Al, CERRETANI D, ROMEOR, DAL PRA P, BOZZO M: L-2-oxothiazolidine-4-carbox-ylic add and glutathione in human immunodeficiency virus. Current Therapeutic Research (1992) 52:461–467.
   Web of Science ®Google Scholar
• BERNARD GR, DUPONT W, EDENS T, HIGGINS S, JIANG K, MORRIS P, PAZ H, RUSSELL J, STEINBERG K, STROUD M, SWINDELL B, WHEELER AP, WRIGHT P: Antioxidants in the acute respiratory distress syndrome (ARDS). Am. Respir. Crit. Care Med. (1994) 149:A241.
   Google Scholar
• Demonstration of clinical efficacy of Procysteine® for the treatment of ARDS.
   Google Scholar